Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?

Annals of Nuclear Medicine

Volumn 19, Issue 5, 2005, Pages 393-398

  Hayashi, Katsumi ^a   Abe, Katsumi ^a   Yano, Fuzuki ^a   Watanabe, Sadahiro ^a   Iwasaki, Yoshie ^a   Kosuda, Shigeru ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Diagnosis and staging; Lung cancer; Mediastinoscopy; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HEALTH CARE COST; HISTOPATHOLOGY; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY;

EID: 24644433445     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03027404     Document Type: Article

References (35)

1. Mountain CF. Value of the new TNM staging system for lung cancer. Chest 1989; 96 (Suppl 1): 47S-49S.
2. Kadri MA, Dussek JE. Survival and prognosis following resection of primary non-small cell bronchogenic carcinoma. Eur J Cardiothorac Surg 1991; 5: 132-136.
3. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-Meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-536.
4. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, De Wever WF, Verbeken EK, et al. FDG PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the location of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med 1998; 25: 1495-1501.
5. Magnani P, Carretta A, Rizzo G, Fazio G, Vanzlli A, Lucignani G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 1999; 40: 741-748.
6. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. New Eng J Med 2000; 343: 254-261.
7. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with Stage I disease. Radiology 2000; 215: 886-890.
8. Fergusson RJ, Gregor A, Dodds R, Kerr G. Management of lung cancer in South East Scotland. Thorax 1996; 51: 569-574.
9. Herder GJ, Verboom P, Smit EF, van Velthoven PC, van den Bergh JH, Colder CD, et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 2002; 57: 11-14.
10. Guyatt GH, Cook DJ, Griffith LE, Miller JD, Todd, TR, Johnston MR, et al. Surgeon's assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer. Ann Thoracic Surg 1999; 68: 309-315.
11. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary nodule (non-small-cell lung carcinoma) in Japan. Chest 2000; 117: 346-353.
12. Abe K, Kosuda S, Kusano S. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma-Reassessment based on the revised Japanese national insurance reimbursement system. Ann Nucl Med 2003; 17: 649-655.
13. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1892.
14. DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology, 5th edn. Philadelphia; Lippincott-Raven Publishers, 1997.
15. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcome and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2002; 20: 263-273.
16. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
17. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 365-369.
18. Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003; 123 (1 Suppl): 221S-225S.
19. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-3460.
20. Sawabata N, Ohta M, Maeda H, Takeda S, Hirano H, Okumura Y, et al. Prognostic significance of persistent mediastinal metastasis following induction therapy in large (> or = 2 cm) N2 or N3 non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2003; 51: 123-129.
21. Tsushima Y, Aoki J, Endo K. Whether and under what conditions FDG-PET might be cost-effective in evaluating solitary pulmonary nodules depicted on lung cancer screening in Japan. Nippon Acta Radiologica 2003; 63: 390-398.
22. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182: 319-323.
23. Ferlito A, Rinaldo A. Controversies in the treatment of N0 neck in laryngeal cancer: Neck dissection, no surgery or sentinel lymph node biopsy? ORL 2000; 62: 287-289.
24. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
25. Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med 1994; 35: 1653-1655.
26. Lee J, Aronchick J, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001; 120: 1791-1797.
27. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-1084.
28. Antoch G, Freudenberg L, Nemat A, Beyer T, Bockisch A. Preoperative staging of non-small cell lung cancer with dual modality PET/CT imaging: a comparison with PET and CT. J Nucl Med 2003; 44: 172p.
29. Malenka DJ, Colice GL, Jacobs C, Beck JR. Mediastinal staging in non-small cell lung cancer. Med Decis Making 1989; 9: 231-242.
30. Eddy R. Cost-effectiveness of CT compared to mediastinoscopy in the preoperative staging of lung cancer. J Can Assoc Radiol 1989; 40: 189-193.
31. The Canadian Lung Oncology Group. Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surg 1995; 60: 1382-1389.
32. The Statistical Information Department of the Welfare & Labor Ministry in Japan. The vital statistics of Japan in 2002. The Welfare Statistics Association Press, Tokyo, 2004.
33. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1900-1904.
34. 18F]fluoro- 2-deoxy-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy? J Thorac Cardiovasc Surg 2003; 126: 1700-1703.
35. Hayashi K, Abe K, Sakaguchi C, Kawauchi T, Kosuda K. Questionnaires on mediastinoscopy for mediastinal FDG uptake in patients with non-small cell lung carcinoma-analysis in the institutions without a PET system. Jpn J Clin Radiol 2005; 50: 281-289.